Global Health Limited announced its unaudited financial results for the third quarter ended December 31, 2025, showcasing strong revenue growth while facing significant challenges from exceptional items related to new Labour Code implementation. The healthcare company's Board of Directors approved the quarterly results at their meeting held on February 04, 2026.

Strong Revenue Performance Continues

The company delivered robust consolidated revenue growth, achieving ₹11.21 billion in Q3FY26 compared to ₹9.43 billion in the corresponding quarter of the previous year. This represents a significant year-on-year growth of 18.8%, demonstrating the company's continued ability to expand its healthcare services despite operational challenges. On a standalone basis, revenue from operations reached ₹9.40 billion compared to ₹8.12 billion in Q3FY25.

Profitability Impacted by Labour Code Implementation

Despite strong top-line performance, the company's profitability faced headwinds during the quarter. Consolidated profit before exceptional items stood at ₹1.56 billion, down from ₹1.89 billion in Q3FY25, representing a 17.5% decline. The quarter was significantly impacted by exceptional items worth ₹366 million on a consolidated basis, primarily related to the implementation of new Labour Codes.

Labour Code Implementation Creates One-Time Impact

The most significant factor affecting Q3FY26 results was the implementation of new Labour Codes notified by the Government of India on November 21, 2025. These codes consolidated 29 existing labour laws and resulted in an exceptional charge of ₹352 million for the standalone entity and ₹366 million on a consolidated basis. This charge relates to incremental provisions for gratuity and compensated absences based on the new regulatory framework.

Board Decisions and Corporate Developments

Beyond financial results, the Board approved several key appointments and recommendations. Mr. Malik Mohd. Ashhab was appointed as Head-Diagnostic Services, bringing over 16 years of diagnostics sector experience to lead the Retail Lab Business of the Group. The Board also recommended re-appointments of Dr. Ravi Gupta and Mr. Rajan Bharti Mittal as Independent Directors for second terms of five years each, along with the appointment of Ms. Shonan Purie Trehan as a Non-Executive Non-Independent Director.

Operational Expansion and Future Outlook

The company continues its expansion efforts, having received physical possession of 3.5 acres of land from Assam Industrial Development Corporation Limited during Q3FY26. Additionally, the company granted 605,500 stock options to eligible employees under its long-term incentive plan, demonstrating continued investment in talent retention and motivation.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, consolidated revenue reached ₹32.51 billion compared to ₹27.61 billion in the corresponding period last year, marking an 17.8% growth. Consolidated net profit for the nine-month period stood at ₹4.12 billion versus ₹3.80 billion in the previous year, showing resilience despite quarterly challenges.

Global health Limited has announced the grant of 4,000 Employee Stock Options (ESOPs) to one employee under its GHL-Employee Long Term Share Based Incentive Plan 2024. The company's Nomination and Remuneration Committee approved this grant during its meeting held on February 03, 2026, in compliance with SEBI regulations.

ESOP Grant Details

The committee meeting, which commenced at 02:30 PM and concluded at 03:00 PM, approved the grant under Part-A of the GHL LTIP 2024 Plan, specifically the GHL Employees Stock Option Scheme, 2024. The grant represents the company's continued commitment to rewarding employee performance and fostering long-term association with key talent.

Plan Structure and Compliance

The GHL LTIP 2024 Plan is designed to reward employees for their association, dedication, and contribution to the company's goals. Global Health Limited views this scheme as a long-term incentive tool that enables employees to become co-owners and create wealth through such ownership. The plan is fully compliant with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Each granted option will result in the allotment of one equity share of Rs. 2 each upon exercise. The purpose of the scheme extends beyond mere compensation, aiming to attract, retain, and motivate key talents by rewarding their performance and encouraging contribution to overall corporate growth and profitability.

Vesting and Exercise Terms

The options granted under the current tranche will vest according to the vesting schedule and conditions outlined in the grant letter, subject to a maximum period of 5 years from the date of grant. Once vested, the options must be exercised within a maximum period of 3 years from the date of vesting of the last instalment of options under the GHL LTIP 2024 Plan.

Regulatory Disclosure

The company has made the necessary disclosures as mandated under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Rahul Ranjan signed the disclosure document, ensuring full regulatory compliance. At this stage, no options have been vested or exercised, and no money has been realized from option exercises.

The grant reflects Global Health Limited's strategic approach to employee retention and motivation, utilizing equity participation as a tool for long-term value creation for both employees and the organization.